GlassScriptPhysician profile
Jeffrey D Cooper
NPI 1457383788
$26,076.70
in general payments reported to CMS, 2019-2025
21 companies · $858 in 2025
The $858 reported for 2025 was more than what 97% of Pediatrics providers received nationally (typical 2025 total: $96.93).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $334 · 2020: $119 · 2021: $320 · 2022: $8,354 · 2023: $15K · 2024: $783 · 2025: $858.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $14K · Food and Beverage: $1,630 · Travel and Lodging: $1,320.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $14,000.00 |
| Food and Beverage | $1,629.54 |
| Travel and Lodging | $1,320.19 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Glaxosmithkline, LLC. | $24,013.50 | 2019-2025 | Bexsero, Penmenvy, Pediarix |
| Supernus Pharmaceuticals, INC. | $594.30 | 2021-2025 | Qelbree, Qelbree |
| Corium, LLC | $406.94 | 2022-2025 | Azstarys |
| Sobi, INC | $179.82 | 2019-2024 | |
| Ironshore Pharmaceuticals INC. | $178.03 | 2019-2023 | Jornay Pm |
| Seqirus USA INC | $121.11 | 2019-2024 | Flucelvax |
| Sanofi Pasteur INC. | $96.39 | 2019-2023 | |
| Pfizer INC. | $79.39 | 2019-2023 | |
| Neos Therapeutics, LP | $60.15 | 2019-2020 | |
| Cranial Technologies, INC | $55.34 | 2024-2025 | Doc Band |
| Adlon Therapeutics L.P. | $49.10 | 2019-2021 | |
| Merck Sharp & Dohme LLC | $43.69 | 2023-2025 | Gardasil 9, Vaxelis, Vaxneuvance |
| Biomarin Pharmaceutical INC. | $36.95 | 2021-2022 | |
| Sumitomo Pharma America, INC. | $26.76 | 2023 | Orgovyx |
| Vertical Pharmaceuticals, LLC | $24.28 | 2019 |
Show all 21 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $22.24 | 2024 | Flumist Quadrivalent |
| Ultragenyx Pharmaceutical INC. | $21.36 | 2021 | |
| Alk-Abello, INC | $18.16 | 2025 | Neffy |
| Phadia US INC. | $16.57 | 2019 | |
| Genentech USA, INC. | $16.47 | 2020 | |
| Kaleo, INC. | $16.15 | 2023 | Auvi-Q |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jeffrey Cooper listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.